ABSTRACT
INTRODUCTION
Acinetobacter baumanii (A baumannii) is a gram-negative, pleomorphic aerobic species commonly isolated from many sources in the environment, including drinking and static water, soil, sewage, food, and the skin of humans and animals. It is usually considered to be an opportunistic pathogen especially in hospitals and healthcare units (1) (2) (3) . A baumannii is a major species, contributing to about 80% of all Acinetobacter hospital-acquired infections (4) . It is often difficult to distinguish between infection and colonization with A baumannii (5) . There is considerable controversy over whether infections caused by this organism leads to unfavourable outcomes; however, it is believed by some clinicians that the recovery of A baumannii in the hospitalized patient is an indicator of severe illness, with an associated mortality of approximately 30% (6) .
One of the reasons that A baumannii-associated disease is predominant among hospitalized patients is its inherent capacity to persist within healthcare facilities, thereby providing reservoirs for transmission and infection. This organism can readily colonize and survive on inanimate surfaces for extended periods of time. It is resistant to desiccation and disinfectants by forming biofilms on abiotic surfaces (7, 8) ; it develops multi-resistance to antibiotics and can acquire and disseminate antibiotic resistance by virtue of its extraordinary ability to accept or donate resistance plasmids (9) (10) (11) and the existence of the virulence factors poses a deleterious effect within the host. As a result, these aforementioned factors have made A baumannii a successful pathogen, thus making the management of A baumanii infections, a public health problem in many countries (12) .
Over the last two decades, A baumannii has gained importance as a leading nosocomial pathogen, especially in critical care units. This organism, which was considered a low-virulence opportunistic pathogen, has turned into a multidrug resistant pathogen with increasing cases of morbidity and mortality. These attributes are alarming to healthcare providers worldwide. Despite the large number of studies and publications on the dynamics of this organism, more surveillance is needed, especially in Iran where there is a relative dearth of information on epidemiological distribution of its virulence factors and antimicrobial resistance dynamics. The aim of this study is to determine the prevalence, antimicrobial resistance and various resistance genes in A baumannii from human clinical samples in Iran using molecular techniques.
MATERIAL AND METHODS

Sample collection
In this cross-sectional study, 500 clinical specimens including: blood (98 samples), phlegm (141 samples), urine (92 samples), pus (134 samples) and CSF (35 samples) were collected from patients on admission at the Payambaran Hospital and Baqiyatallah Hospital in the city of Tehran, Iran, over a period of six months (from September 2012 to March 2013). These specimens were collected by a laboratory technician, properly labelled and then were transported immediately to the Microbiology laboratory.
Isolation and identification of Acinetobacter baumannii I solation of A baumannii was done using MacConkey and blood agar plate culture for all the specimens. The nonhaemolytic, opaque, creamy colonies on blood agar and nonlactose fermenting colonies on MacConkey agar were further sub-cultured on MacConkey agar and incubated for another 24 hours at 37 º C to obtained pure colonies (13) . The isolated organisms were identified based on colony morphology, microscopic study and various biochemical tests according to standard laboratory methods (13 
Conventional polymerase chain reaction
The reverse and forward primers, size of product as previously published used for the detection of 16S-23S ribosomal DNA, antimicrobial resistant genes in A baumannii in the study are presented in Table 1 . Polymerase chain reaction (temperature and volume) for detection of 16S-23S ribosomal DNA, antimicrobial resistance genes in A baumannii are also summarized in Table 2 . The PCR amplified products (10 µL) were subjected to electrophoresis in a 1.5% agarose gel in 1X TBE buffer at 80V for 30 minutes, stained with solution of ethidium Bromide and examined under ultraviolet illumination (Uvitec, UK).
Statistical analysis
The prevalence analysis was computed in percentage and presented using descriptive statistics. 
Resistance in Acinetobacter baumannii
Streptomycin aadA1 (F) TATCCAGCTAAGCGCGAACT 447 15 (R) ATTTGCCGACTACCTTGGTC Gentamycin aac(3)-IV (F) CTTCAGGATGGCAAGTTGGT 286 15 (R) TCATCTCGTTCTCCGCTCAT Sulfonamide sul1 (F) TTCGGCATTCTGAATCTCAC 822 15 (R) ATGATCTAACCCTCGGTCTC Beta-lactams blaSHV (F) TCGCCTGTGTATTATCTCCC 768 15 (R) CGCAGATAAATCACCACAATG Beta-lactams CTX-M (F) TGGCCAGAACTGACAGGCAAA 462 15 (R) TTTCTCCTGAACGTGGCTGGC Chloramphenicol cat1 (F) AGTTGCTCAATGTACCTATAACC 547 15 (R) TTGTAATTCATTAAGCATTCTGCC Chloramphenicol cmlA (F) CCGCCACGGTGTTGTTGTTATC 698 15 (R) CACCTTGCCTGCCCATCATTAG Tetracycline tet(A) (F) GGTTCACTCGAACGACGTCA 577 15 (R) CTGTCCGACAAGTTGCATGA Tetracycline tet(B) (F) CCTCAGCTTCTCAACGCGTG 634 15 (R) GCACCTTGCTGATGACTCTT Trimethoprim dfrA1 (F) GGAGTGCCAAAGGTGAACAGC 367 15 (R) GAGGCGAAGTCTTGGGTAAAAAC Quinolones Qnr (F) GGGTATGGATATTATTGATAAAG 670 15 (R) CTAATCCGGCAGCACTATTTA Carbiniciline Imp-F 5'-GAATAGAATGGTTAACTCTC-3' 188 16 Imp-R 5'-CCAAACCACTAGGTTATC-3' Carbiniciline Vim-F 5'-GTTTGGTCGCATATCGCAAC-3' 382 16 Vim-R 5'-AATGCGCAGCACCAGGATAG-3' Carbiniciline Sim-F 5'-GTACAAGGGATTCGGCATCG-3' 569 16 Sim-R 5'-GTACAAGGGATTCGGCATCG-3' Oxacillinases Oxa-51-like-F 5'-TAATGCTTTGATCGGCCTTG-3 353 16 Oxa-51-like-R 5'-TGGATTGCACTTCATCTTGG-3' Oxacillinases Oxa-23-like-F 5'-GATCGGATTGGAGAACCAGA-3' 501 16 Oxa-23-like-R 5'-ATTTCTGACCGCATTTCCAT-3' Oxacillinases Oxa-24-like-F 5'-GGTTAGTTGGCCCCCTTAAA-3' 246 16 Oxa-24-like-R 5'-AGTTGAGCGAAAAGGGGATT-3' Oxacillinases Oxa-58-like-F 5'-AAGTATTGGGGCTTGTGCTG-3' 599 16 Oxa-58-like-R 5'-CCCCTCTGCGCTCTACATAC-3' A baumannii detection 16S-23S ribosomal DNA (F) CATTATCACGGTAATTAGTG 208 17 (R) AGAGCACTGTGCACTTAAG
RESULTS
During the study period, a total of 121 cultures of A baumannii were detected out of 500 samples, representing 24.20% period prevalence. A baumannii was detected from all the sample groups, higher prevalence was observed in blood (43.87%), phlegm (24.11%) and urine (23.11%) while relatively low prevalence was detected in CSF (17.14%) and pus (11.94%) [ Table 3 ] (Fig.1) .
Different antimicrobial resistance genes detected from this study were presented in Table 4a, Table 4b and Fig 2; highest detection for resistant genes was observed for tetA (58.67%), aac(3)-IV (56.19%), sul1(55.37%) and dfrA1 (48.76%).
Relatively low detection was observed for aad A1, blagenes (blaSHV, blaCTX-M, blaOXA-like, blaVIM, blaSIM and blaIMP), lowest detection was found for cat1 and cmlA while no qnr gene was detected in this study. Antibiotic resistance profile of A baumannii is presented in Resistance in Acinetobacter baumannii 
DISCUSSION
A baumannii is one of the commonly isolated non-fermenting bacteria in human specimens, especially of nosocomial origin after Pseudomonas aeruginosa. Its infections are uncommon but, when they occur, it is usually associated with organ systems with high fluid content eg respiratory tract, CSF, peritoneal fluid and urinary tract (18) (19) (20) . Just as observed in this study, A baumannii was detected from all sample groups from organs with fluid content including blood, urine and CSF. Jaggi et al (18) and Dash et al (21) have also reported the detection of this organism from pus, urine, sputum, blood and body fluids in tertiary hospitals in India. Colonization potentials as well as healthcare associated infection and outbreaks of CSF:cerebrospinal fluid this organism have been reported (12) . Detection of Acinetobacter from these samples may suggest either an on-going infection or colonization of organ sources with A baumannii. However, detection of A baumannii in blood samples suggests that Acinetobacter cannot exist as a colonizer in blood, it would have a higher pathogenic and septicaemic potential at this site. Since these patients are on hospital admission, there are possibilities that they may have acquired this organism from hospital environments such as surfaces and medical equipments and even beddings. Detection of this organism from the patients from the two hospitals may indicate or suggests that, these hospitals are contaminated with Acinetobacter with risk of nosocomial transmission and possibilities of future hospital outbreak. One of the challenges with A baumannii is its capacity to acquire myriads of antimicrobial-resistance genes rapidly, leading to multi-drug resistance, just as observed in this study. A baumannii detected in this study was resistant to all antibiotics tested in different proportion and were also found to carry different resistant genes to different classes of ant- Khamesipour et al ibiotics, thus, supporting the multi-drug resistant characteristic of A baumannii. Widespread use of antimicrobials within healthcare facilities have been considered to be a major factor in the emergence of antimicrobial resistance among Acinetobacter strains, in particular, the wide use of extendedspectrum cephalosporins and quinolones (22) . From this study, Acinetobacter baumannii resistant to tetracycline represented the highest antibiotic resistance recorded. Both tetA and tetB genes represented the most prevalent resistant genes observed in this study. This resistant pattern to tetracycline could be due to the indiscriminate use of this antibiotic either within the hospitals or the communities. The increased tetracycline resistance and tetracycline resistant genes recorded in the present study, support the fact that tetA confers resistance to tetracycline only, while tetB in addition to tetracycline confers resistance to minocycline (23, 24) . This resistance to tetracycline and its derivatives is reported to be due to efflux pumps or ribosomal protective mechanisms (25) . In this study, the prevalence of tetA was observed to be higher than tetB, this is at variant to 66% and 13.6% reported for tetB and tetA, respectively by Marti et al (26) . Tetracycline resistant A baumannii has been reported from Iran (27, 28) , however, it has been reported that, in most clinical practices, use of tetracycline as therapy against A baumannii infections is not common but high resistance to tetracycline is common among A baumannii isolates (29, 30) and the result of this study confirmed this claim.
The resistance among A baumannii strains to β-lactam antibiotics although relatively lower, is of great concern. The β-lactams are broadly accepted for treatment; because of their availability, broad spectrum activities, reduced risk of side-effects, and importantly, their relatively low cost. Low resistance (4-7%) to carbapenems ie imipenem and meropenem and close to 20% resistance to cephalosporin (cephalotin and ceftazidime) observed in the present study is lower than over 90%reported to by Jaggi et al, in India (18), Japoni-Nejad et al, (27) and Safari et al (31) in I ran. Reduced resistance to cephalosporins and carbapenems may be due to non-use or judious use of these antibiotics in affected patients. This may also suggests that, carbapenems will be effective drugs in the management of Acinetobacter infections or in outbreaks in these hospitals. This finding has also been reported in most studies in Iran (32) (33) (34) . The detection of β-lactamases such as blaSHV, blaCTXM, blaOXA-like (6.61-23.14%) and Metallo-bêta lactamases (MBL) ie VI M, SI M and I MP (8.26-14.04%) indicates and support the fact that A baumannii are ESBL and MBL producers.
Acinetobacter are known to produce a myriad of β-lactamases. The main mechanisms of resistance to extendedspectrum cephalosporins in A baumannii have been reported to be due to the over-expression of chromosomal cephalosporinases and plasmid-encoded Ambler class A, B, and D β-lactamases (35) . The blaOXA gene has been considered as a natural component of the species chromosome and has been used in identification of A baumannii (36) .
Previous report indicates blaOXA-51 genes are present in the vast majority of isolates of A baumannii and may also be associated with resistance to carbapenems (35) , however, in this study only 7.43%-11.57% of A baumannii carried blaOXA genes. There has been some debate as to whether they are present in all isolates of this species (37) .
Although, in this study, 4-7% of A baumannii are resistant to carbapenems, almost double of this organism (8.26-14.04%) were observed to be a carriers of VIM, SIM and IMP; this may suggest the role of blaOXA genes in carbapenem resistance. Also, this may suggest the potentials of this organism to increase resistance to carbapenems in the near future in these hospitals. This increase in the number of MBLs in A baumannii is a concerned development in the global emergence of MBL resistance to β-lactams.
In this study, tobramycin and amikacin showed better activities and higher sensitivities to A baumannii compared to streptomycin and gentamycin, A baumannii resistance to aminoglycosides is relatively low. Akers et al (38) have reported higher sensitivities of tobramycin to A baumannii. While Dauner et al (39) and Mostofi et al (40) reported reduced susceptibility to gentamycin against Acinetobacter.
Amikacin showed higher sensitivity in this study compare to that reported by other studies (41) . Susceptibility to aminoglycosides has changed a lot in recent years, gentamycin used to be an active agent against Acinetobacter infections, but now this organism has acquired resistance against this antibiotic. This resistance to aminoglycosides in A baumannii has been reported to be mediated principally by aminoglycoside-modifying enzymes [AMEs] (42) . And the detection of aac(3)-IV and aadA1 AMEs in this study corroborates this report. These AMEs have also been reported from different parts of the world including, Iran (34, 42, 43) .
Quinolone resistance in A baumannii observed in this study is relatively low; this shows that quinolones have higher sensitivity to A baumannii. Non-detection of qnr gene in this study corroborates other reports worldwide (44) (45) (46) . This plasmid mediated-quinolone resistance gene (PMQR) has not yet been reported in A baumannii. Acinetobacter baumannii resistance to quinolones has been reported to be due to modifications in the structure of DNA gyrase secondary to mutations in the quinolone resistance-determining regions of the gyrA and parC genes (47, 48) . Higher resistance of A baumannii to trimethoprim and co-trimoxazole (> 50%) observed in this study, have also been reported elsewhere (49, 50) . Indiscriminate use of these antibiotics and higher detection of sul1 and dfrA1 resistant genes in this organism against sulfonamides and trimethoprim may account for this. While chloramphenicol, nitrofurantoin, azithromycin, rifampin and erythromycin all showed higher sensitivities against A baumannii, their therapeutic use in Acinetobacter infections is not widely reported and in most cases, their use maybe as adjunct therapy.
In conclusion, detection of Acinetobacter from different samples suggest either an on-going infection or colonization of organ sources with A baumannii. Resistance was observed in all antibiotics tested in different proportion and there were also different resistant genes to different class of antibiotics, thus, supporting the multi-drug resistant characteristic of A baumannii. Multi-drug resistant Acinetobacter infections are posing an increasing threat to the population in these communities. Carbapenems provide an effective option against infections caused by resistant A baumannii.
